heart failure: benefits of combo Rx for HFpEF
A recent mathematical analysis estimated the benefits of combined medical therapy in heart failure with mildly reduced and preserved ejection fraction ( see chf benefits of combo Rx in HFpEF circ2022 in dropbox or DOI: 10.1161/CIRCULATIONAHA.121.058929) Details: -- this analysis was based on a few important prior studies: -- PARAGON-HF: assessed 4822 patients having heart failure with preserved ejection fraction (HFpEF) >45% who were randomized to sacubitril-valsartan (97 mg/103 mg twice a day) versus valsartan alone (160 mg twice a day). The primary outcome was a composite of total hospitalization for heart failure and death from cardiovascular causes: almost statistically significantly different, with rate ratio of 0.87 (0.75-1.01), p=0.06. However, the rate of hospitalizations for heart failure was a statistically significant 15% decrease with rate ratio 0.85 (0.72-1.00); the NYHA HF class improved in 15% of ...